January 13, 2012 — Accuray said this week there had been significant momentum in global adoption of its CyberKnife robotic radiosurgery system and TomoTherapy system. Along with the company's short and long-term growth strategy, this news was presented by Accuray President and CEO Euan Thomson, Ph.D., as part of the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.
Accuray has taken its installed base from zero to over 600 commercially released systems in approximately a decade. That momentum has continued in the United States and internationally as a result of growing demand for effective and efficient radiation oncology treatments in emerging growth markets, and as the growing body of clinical evidence mounts supporting the advantages of image-guided radiosurgery and IMRT technologies.
As Accuray's earliest CyberKnife and TomoTherapy systems reach the end of their life cycle, new opportunities emerge for organic replacement business, along with the opportunity to capture the replacement market for older, pre-existing linacs at centers that desire newer, state-of-the-art capabilities. As the installed base grows, so too does Accuray's recurring revenue streams through service contracts, which together represent consistent annual growth.
By combining the two radiation oncology technologies focused on personalized patient care, Accuray has seen growing interest in both the TomoTherapy and CyberKnife technologies. The company's installations currently span 33 countries.
For more information: www.accuray.com
April 25, 2024 
